Total cholesterol, lipoprotein, and triglyceride levels in tumor necrosis factor inhibitor-treated patients with psoriasis, psoriatic arthritis, or rheumatoid arthritis

Int J Dermatol. 2015 Oct;54(10):e442-5. doi: 10.1111/ijd.12921. Epub 2015 Jul 31.

Authors

Jashin J Wu¹, Christopher G Rowan², Judith D Bebchuk³, Mary S Anthony⁴

Affiliations

¹ Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, USA. [email protected].
² American Medical Group Association, Alexandria, VA, USA.
³ Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
⁴ RTI Health Solutions, Durham, NC, USA.

PMID: 26234307
DOI: 10.1111/ijd.12921

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Arthritis, Psoriatic / blood*
Arthritis, Psoriatic / drug therapy*
Arthritis, Rheumatoid / blood*
Arthritis, Rheumatoid / drug therapy*
Cholesterol / blood
Drug Therapy, Combination
Humans
Immunosuppressive Agents / therapeutic use
Lipoproteins, HDL / blood
Lipoproteins, LDL / blood
Methotrexate / therapeutic use
Psoriasis / blood
Psoriasis / drug therapy
Retrospective Studies
Triglycerides / blood
Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

Immunosuppressive Agents
Lipoproteins, HDL
Lipoproteins, LDL
Triglycerides
Tumor Necrosis Factor-alpha
Cholesterol
Methotrexate